Weight Loss From GLP-1 Drugs May Help Women Land Jobs and Relationships, Study Finds

New research suggests something surprising about GLP-1 drugs like Ozempic and Wegovy. Their effects might reach far beyond the scale.

A working paper from the National Bureau of Economic Research found something notable. Women who lost weight on these medications were more likely to start new relationships. They were also more likely to land jobs. Economist Rebecca Diamond led the analysis. It hasn’t been peer-reviewed yet. Still, the findings offer a rare look at how weight loss shapes real-world opportunities.

The study drew on data from the Understanding America Study. That’s a nationwide panel of about 15,000 adults. Diamond compared 242 women who started GLP-1 treatment for weight loss with 850 similar women who wanted the drugs but hadn’t started yet. She excluded anyone who began treatment mainly to manage type 2 diabetes. A diabetes diagnosis alone could otherwise skew the results.

Here’s what stood out. Single women who started GLP-1 therapy were 18.3 percentage points more likely to marry or move in with a partner. That number climbed even higher over time. It reached 28.6 percentage points a year and a half after starting treatment. Meanwhile, women who were already in relationships saw no real change. Their odds of breaking up or divorcing stayed flat.

Employment followed a similar pattern. Women who weren’t working before starting treatment saw their employment rate jump by 13.2 percentage points. Again, the effect grew stronger with time. It hit nearly 27 percentage points in the long run. These women also worked almost 10 more hours per week than before.

But there’s a catch. Women who already had jobs didn’t benefit the same way. Their employment numbers actually dipped slightly. They also switched jobs less often. Diamond suspects some of this comes down to insurance. Many employer health plans offer coverage for GLP-1 prescriptions. So switching jobs could mean losing that coverage, and given the cost of these drugs without insurance, that’s a real concern for many women.

So what does this all mean? Diamond thinks it points to something she calls a “first impression discount.” In other words, weight may matter most when someone is meeting you for the first time. That could be a hiring manager. It could be a potential partner. Once people already know you, your weight seems to matter a lot less.

That’s an important distinction. Existing relationships and jobs didn’t show much change at all. The real shifts happened when women formed brand-new connections, not when they maintained old ones.

Of course, this study can’t prove discrimination caused these outcomes. It only shows a pattern. It doesn’t show a cause. Diamond herself is careful here. She notes that other factors could be at play, like improved energy levels or better physical mobility after weight loss.

It’s also worth remembering what these drugs actually are. GLP-1 medications like semaglutide and tirzepatide are prescription-only treatments. The FDA has approved them for type 2 diabetes. Some formulations are also approved for weight management. They work by mimicking hormones that control appetite and blood sugar. Side effects like nausea and fatigue are common. These may explain some of the health complaints reported by women in the study.

There’s a bigger issue lurking here too. The women who started GLP-1 treatment early tended to be more financially secure. That raises real concerns about access to care for obesity treatment more broadly. If these medications truly open doors socially and professionally, unequal access could widen existing inequalities instead of narrowing them.

There’s also an ethical wrinkle worth mentioning. If weight-based bias is real, should the answer be encouraging more people to take medication? Or should the focus fall on the bias itself? Diamond raises this question without offering an easy answer.

One more caveat matters here. Not everyone stuck with treatment. Only 53% of the women who started GLP-1 drugs were still taking them at follow-up. That inconsistency makes it harder to separate the effects of continued use from simply starting treatment. Larger, controlled clinical trials will be needed to confirm these patterns more rigorously.

Overall, the study adds an interesting piece to a much larger conversation about weight, bias, and opportunity. It doesn’t settle the debate. But it does suggest that first impressions carry real weight, quite literally, in ways we might not expect.